Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?
b'Host: Nikhil I. Khushalani, MD
\\n\\n\\n \\n
This program is designed to improve clinicians\\u2019 knowledge of the latest clinical trial data surrounding the use of immunotherapy for the adjuvant treatment of patients with melanoma. The program addresses clinical challenges faced by oncologists/surgeons, including selecting appropriate patients, determining optimal treatment schedules and dosing, and managing toxicity.
'